Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Sophion and ChanTest announce ion channel cell line collaboration


Vancouver, BC (June 24, 2008). Today, Sophion Bioscience and ChanTest Corporation announced a landmark agreement regarding ion channel cell lines for ion channel drug discovery and safety testing at the 6th Annual Ion Channel Retreat. Under the terms of this agreement, Sophion has the right to provide ion channel cell lines from ChanTest that are optimized for Sophion’s QPatch automated patch clamp systems.

“We are thrilled to partner with Sophion in the process of optimizing the automated patch clamp world,” said Dr. Arthur “Buzz” Brown, CEO of ChanTest. “The combination of our extensive ion channel cell line library and Sophion’s Qpatch systems is new and has the potential to revolutionize the drug discovery process.”

Dr. Morten Sunesen, Sophion’s Director of Customer Relations, added, “A critical aspect of a thriving QPatch assay relates to having optimized cell lines. This partnership between Sophion and ChanTest allows Pharma and Biotech groups in the ion channel drug discovery industry to quickly get usable data with a great variety of ion channel cell lines.”

About Sophion Bioscience

Sophion Bioscience, a leader in the automated patch clamp field, helps drug discovery companies make more and better drugs, faster. Sophion’s sole focus is to provide advanced products and integrated solutions for automated patch clamping Sophion’s QPatch 16 and QPatch HT (48-channels) provide high-quality patch clamp data on a truly industrial basis. Only the QPatch has an integrated cell preparation and QPlate exchange facilities enabling several hours of unattended operation. The unique microfluidic flow channel system implemented in the QPlates enables fast liquid exchange around each cell and provides the option to test multiple compounds or increasing concentrations on the same cell.

About ChanTest

ChanTest is the preeminent ion channel services company. ChanTest has tested more than 13,000 compounds for more than 300 clients around the world – pharmaceutical and biotech companies large and small. In HTStec Ion Channel Trends Surveys for 2006 and 2007, ChanTest was voted the “world’s most trusted ion channel services company”. ChanTest is building and validating the most complete ion channel library extant. “Books” in the library are optimized on Qpatch HT and all other major automated electrophysiology platforms. The ion channel “books” can be arranged in panels according to tissue (cardiac channel panel), therapeutic area (pain channel panel) and ion channel families (Nav1.x channel panel). These panels are used in preclinical profiling and risk assessment of the heart and cardiovascular system, CNS, and respiratory, G-I and G-U systems.

For more information, please contact: Morten Sunesen, Ph.D., Director, Customer
Relations, Sophion Bioscience A/S, e-mail: msu@sophion.dk or telephone: +45-
4460-8866 or Robert D. Schultek, Vice President, Business Development, ChanTest
Corporation, email: rschultek@chantest.com or telephone: +1 216-332-1665.


Publisher Contact Information:

Sophion Bioscience A/S
+45-4460-8866
msu@sophion.dk

Company profile of Sophion Bioscience A/S
Past press releases of Sophion Bioscience A/S.

Data


25,747
Tech investments
From our Online Data Service
16,670
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
May 24€4.1MArtificial Intelligence
May 24€0.6MArtificial Intelligence
May 24€3.0MMedical devices
May 24€9.0MRobotics
May 23N/AConsumer applications
May 23€4.5MInternet services
May 23€12.0MOther Biotechnology & Healthcare

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.